Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - Kymab

Drug Profile

Research programme: monoclonal antibody therapeutics - Kymab

Alternative Names: Anti-OPG Antibody; KY 1003; KY 1006; KY 1007; KY 1009; KY 1015; KY 1016; KY 1017; KY 1020; KY 1021; KY 1031; KY 1034; KY 1040; KY 1041; KY 1047; KY 1050; KY 1055; KY 1081; KY 7001; KY 7002; KY 7003; KY 7004; KY 7005; KY 7006; Ky3

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants; Inducible T-cell co-stimulator protein antagonists; Programmed cell death-1 ligand-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Haematological disorders; Inflammatory bowel diseases; Pulmonary hypertension; Systemic lupus erythematosus
  • Discontinued Cardiovascular disorders; Dyslipidaemias; Fibrosis; Graft-versus-host disease; Infections; Pain

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Pulmonary-hypertension in United Kingdom (Parenteral)
  • 09 Apr 2021 Kymab has been acquired by Sanofi
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top